Opinions
Jim Cramer - Mad Money
23andMe
ME-Q
BUY
Sep 29, 2021
It's a genetic testing company with subscription services to let you know how your genes could effect your health. They went public last June, but has fallen since from $11 to $8. He doesn't understand why. Gene sequencing is the future of medicine and this company holds a treasure trove of data (kept private) that could be applied in medicine.
$8.530
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising